JP2008516004A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008516004A5 JP2008516004A5 JP2007543041A JP2007543041A JP2008516004A5 JP 2008516004 A5 JP2008516004 A5 JP 2008516004A5 JP 2007543041 A JP2007543041 A JP 2007543041A JP 2007543041 A JP2007543041 A JP 2007543041A JP 2008516004 A5 JP2008516004 A5 JP 2008516004A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- salt
- radioisotope
- granule
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000003556 assay Methods 0.000 description 2
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61680504P | 2004-10-07 | 2004-10-07 | |
| US60/616,805 | 2004-10-07 | ||
| PCT/US2005/035921 WO2007050050A2 (en) | 2004-10-07 | 2005-10-06 | Thiazolyl mglur5 antagonists and methods for their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014184615A Division JP2015013885A (ja) | 2004-10-07 | 2014-09-10 | チアゾリルｍｇｌｕｒ５アンタゴニスト及びそれらの使用のための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008516004A JP2008516004A (ja) | 2008-05-15 |
| JP2008516004A5 true JP2008516004A5 (enExample) | 2014-10-30 |
| JP5635727B2 JP5635727B2 (ja) | 2014-12-03 |
Family
ID=37968242
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007543041A Expired - Fee Related JP5635727B2 (ja) | 2004-10-07 | 2005-10-06 | チアゾリルｍｇｌｕｒ５アンタゴニスト及びそれらの使用のための方法 |
| JP2014184615A Pending JP2015013885A (ja) | 2004-10-07 | 2014-09-10 | チアゾリルｍｇｌｕｒ５アンタゴニスト及びそれらの使用のための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014184615A Pending JP2015013885A (ja) | 2004-10-07 | 2014-09-10 | チアゾリルｍｇｌｕｒ５アンタゴニスト及びそれらの使用のための方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US7879882B2 (enExample) |
| EP (2) | EP1893608B1 (enExample) |
| JP (2) | JP5635727B2 (enExample) |
| CN (1) | CN101223166B (enExample) |
| AT (1) | ATE520692T1 (enExample) |
| AU (1) | AU2005336513B2 (enExample) |
| CA (1) | CA2583572C (enExample) |
| ES (1) | ES2369783T3 (enExample) |
| WO (1) | WO2007050050A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005336513B2 (en) | 2004-10-07 | 2012-08-09 | Merck Sharp & Dohme Llc | Thiazolyl mGluR5 antagonists and methods for their use |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| TW201124391A (en) * | 2009-10-20 | 2011-07-16 | Lundbeck & Co As H | 2-substituted-ethynylthiazole derivatives and uses of same |
| WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
| AR080055A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1 |
| ES2527849T3 (es) | 2010-02-02 | 2015-01-30 | Novartis Ag | Derivados de ciclohexilamida como antagonistas del receptor de CRF |
| US8420661B2 (en) | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| US8772300B2 (en) * | 2011-04-19 | 2014-07-08 | Hoffmann-La Roche Inc. | Phenyl or pyridinyl-ethynyl derivatives |
| JP5753626B2 (ja) * | 2011-04-26 | 2015-07-22 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ピラゾリジン−３−オン誘導体 |
| SI2702051T1 (sl) * | 2011-04-26 | 2015-06-30 | F. Hoffmann-La Roche Ag | Etinilni derivati kot pozitivni alosteriäśni modulatorji mglur5 |
| WO2014121883A1 (en) | 2013-02-07 | 2014-08-14 | Merck Patent Gmbh | Substituted acetylene derivatives and their use as positive allosteric modulators of mglur4 |
| UA116023C2 (uk) * | 2013-07-08 | 2018-01-25 | Ф. Хоффманн-Ля Рош Аг | Етинільні похідні як антагоністи метаботропного глутаматного рецептора |
| WO2015188368A1 (en) * | 2014-06-13 | 2015-12-17 | Merck Sharp & Dohme Corp. | Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles |
| PT3303316T (pt) | 2015-06-03 | 2020-04-27 | Hoffmann La Roche | Derivados de etinilo |
| EP3661509A4 (en) | 2017-08-04 | 2021-01-13 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATING THE SPLICE |
| CN114007613A (zh) | 2019-02-05 | 2022-02-01 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| JP7551629B2 (ja) | 2019-02-05 | 2024-09-17 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| CN113677344A (zh) | 2019-02-06 | 2021-11-19 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| WO2020163647A1 (en) | 2019-02-06 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6774138B2 (en) | 1999-08-31 | 2004-08-10 | Merck & Co., Inc. | Thiazolyl(pyridyl)ethyne compounds |
| US7365074B2 (en) * | 1999-08-31 | 2008-04-29 | Merck & Co., Inc. | Pyridazine, pyrimidine and pyrazine ethyne compounds |
| US6956049B1 (en) * | 1999-08-31 | 2005-10-18 | Merck & Co., Inc. | Methods of modulating processes mediated by excitatory amino acid receptors |
| EP1214303A1 (en) * | 1999-08-31 | 2002-06-19 | Merck & Co., Inc. | Heterocyclic compounds and methods of use thereof |
| US7462619B2 (en) * | 1999-08-31 | 2008-12-09 | Merck & Co., Inc. | Pyridazine, pyrimidine and pyrazine ethyne compounds |
| US6903005B1 (en) * | 2000-08-30 | 2005-06-07 | Micron Technology, Inc. | Method for the formation of RuSixOy-containing barrier layers for high-k dielectrics |
| US6551270B1 (en) | 2000-08-30 | 2003-04-22 | Snowden Pencer, Inc. | Dual lumen access port |
| AU2003285957A1 (en) * | 2002-10-24 | 2004-05-13 | Merck & Co., Inc. | Alkyne derivatives as tracers for metabotropic glutamate receptor binding |
| AU2005336513B2 (en) * | 2004-10-07 | 2012-08-09 | Merck Sharp & Dohme Llc | Thiazolyl mGluR5 antagonists and methods for their use |
-
2005
- 2005-10-06 AU AU2005336513A patent/AU2005336513B2/en not_active Ceased
- 2005-10-06 US US11/664,902 patent/US7879882B2/en active Active
- 2005-10-06 EP EP05858618A patent/EP1893608B1/en not_active Expired - Lifetime
- 2005-10-06 JP JP2007543041A patent/JP5635727B2/ja not_active Expired - Fee Related
- 2005-10-06 CN CN2005800415189A patent/CN101223166B/zh not_active Expired - Fee Related
- 2005-10-06 EP EP11167527.8A patent/EP2380889B1/en not_active Expired - Lifetime
- 2005-10-06 WO PCT/US2005/035921 patent/WO2007050050A2/en not_active Ceased
- 2005-10-06 AT AT05858618T patent/ATE520692T1/de not_active IP Right Cessation
- 2005-10-06 ES ES05858618T patent/ES2369783T3/es not_active Expired - Lifetime
- 2005-10-06 CA CA2583572A patent/CA2583572C/en not_active Expired - Lifetime
-
2011
- 2011-01-28 US US13/016,304 patent/US8242143B2/en not_active Expired - Lifetime
-
2012
- 2012-07-26 US US13/558,537 patent/US8609852B2/en not_active Expired - Lifetime
-
2014
- 2014-09-10 JP JP2014184615A patent/JP2015013885A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008516004A5 (enExample) | ||
| JP2021063088A5 (enExample) | ||
| JP2006526031A5 (enExample) | ||
| JP2009545527A5 (enExample) | ||
| JP2021001196A5 (enExample) | ||
| IL259851A (en) | Compounds and methods of inhibiting antidepressant nhe mediator in the treatment of disorders associated with fluid retention or overload of salts and gastrointestinal disorders | |
| JP2009502743A5 (enExample) | ||
| JP2013518107A5 (enExample) | ||
| JP2012031147A5 (enExample) | ||
| JP2020097577A5 (enExample) | ||
| JP2010077141A5 (enExample) | ||
| JP2018534348A5 (enExample) | ||
| JP2013519632A5 (enExample) | ||
| JP2005518413A5 (enExample) | ||
| JP2007302683A5 (enExample) | ||
| JP2010501534A5 (enExample) | ||
| JP2016065086A5 (enExample) | ||
| JP2016006096A5 (enExample) | ||
| JP2012502037A5 (enExample) | ||
| JP2011527299A5 (enExample) | ||
| WO2006082523A3 (en) | Pharmaceutical sustained release composition of metformin | |
| JP2008519768A5 (enExample) | ||
| JP2008513510A5 (enExample) | ||
| BR0111868A (pt) | Composições farmacêuticas | |
| JP2004532828A5 (enExample) |